In today’s briefing:
- The Beat Ideas: Laurus Labs
- Acelyrin and Alumis Merger Faces Activist Challenges Amid Tang’s Higher Offer and Market Skepticism
- Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent
- Insulet Corporation: Leveraging Direct-to-Consumer Channels To Boost Product Awareness & Usage!
- Globus Medical: Nevro Acquisition & Market Expansion Driving Our ‘Outperform’ Rating!
- CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial
- REVB: 2025 Is the Year for Measurable Progress
The Beat Ideas: Laurus Labs
- The company is expected to see multiple capacity expansions coming online in FY26, with ramp-up occurring throughout FY26 and FY27 onwards.
- Currently, execution challenges and unavoidable delays have impacted the company’s revenue and margin trajectory, resulting in depressed margins on a short-term basis.
- As new projects come online and product ramp-ups occur, it expects revenue and margin expansion, ultimately reflecting in the bottom line due to the increased gross block & new products.
Acelyrin and Alumis Merger Faces Activist Challenges Amid Tang’s Higher Offer and Market Skepticism
- Acelyrin agreed to an all-stock merger with Alumis, valued at $2.2/share, requiring shareholder approval with 24% support.
- Tang’s $3/share cash offer was rejected; activists hold 11% stake, acquired near $2/share, with unclear agendas.
- ALMS merger has 62% support; Ayurmaya Capital holds 22% of ALMS, 9% of SLRN, and supports the merger.
Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent
- Cochlear Ltd (COH AU) now expects FY25 underlying net profit to be at the lower end of A$410–430M guidance range due to lower services revenue and higher cloud-related investment.
- Despite 5% growth in H1FY25, Cochlear reiterated that “solid market growth rates to drive cochlear implant unit growth of around 10% in FY25.”
- Cochlear is expected to release next-generation cochlear implant in mid-2025. The introduction of the new off-the-ear Nucleus Kanso 3 sound processor is expected to contribute to services revenue from FY26.
Insulet Corporation: Leveraging Direct-to-Consumer Channels To Boost Product Awareness & Usage!
- Insulet Corporation concluded a robust fiscal year 2024 with notable achievements in both the fourth quarter and the full year.
- The company achieved a milestone by surpassing $2 billion in revenue, marking its ninth consecutive year with at least 20% constant currency revenue growth.
- Key drivers of this growth include the strong performance and adoption of the Omnipod 5 insulin delivery system, both in the U.S. and expanding international markets.
Globus Medical: Nevro Acquisition & Market Expansion Driving Our ‘Outperform’ Rating!
- Globus Medical, a company specializing in medical devices and technology, closed 2024 with notable positive performance metrics, as illustrated in their financial results.
- Revenue achieved a record high of $2.519 billion, marking an impressive 61% increase compared to the prior year.
- This was accompanied by an increase in non-GAAP EPS to $3.04, a substantial rise of 31% even with a 20% expansion in diluted shares versus the previous year.
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial
- On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
- The collaboration calls for Abbott to share insights from recent HeartMate 3 trials while also assisting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise.
- Having the support of Abbott will be a huge advantage for Cadrenal and should ensure that the TECH-LVAD trial is performed with the maximum efficiency as Abbott has a tremendous amount of experience working with this patient population.
REVB: 2025 Is the Year for Measurable Progress
- Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.
- The company announced its 2024 annual results, which showed good cash on its balance sheet and reminded investors that a pivotal trial is underway.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
